Test drug to reduce stomach side effects during lymphoma chemotherapy
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 3 trial studies whether a proton pump inhibitor (a stomach acid blocker) works better than histamine-blocking medicines when added to chemotherapy for DLBCL lymphoma. The goal is to improve how well chemotherapy is tolerated or how the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diffuse large B-cell lymphoma (DLBCL).
- You do not have other major health problems that could interfere with the study.
- You must not be pregnant (people who could become pregnant need special planning).
- You must not currently have a peptic ulcer (an open sore in the stomach or small intestine).
- You should not have severe heart disease.
- You should not have osteoporosis (weak bones).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
This study compares two lymphoma treatments: mini-CHOP alone versus mini-CHOP plus a drug called polatuzumab vedotin. It aims to see which regimen works better and is tolerable for older or frail people with certain types of aggressive B-cell lymphoma.
This Phase 3 study tests whether a short “pre-treatment” with prednisone, with or without vitamin D, can improve outcomes when followed by standard lymphoma chemo. It aims to see if adding vitamin D early can help older adults tolerate or benefit from treatment for specific lymphoma types.
This Phase 2 trial tests a PD-1 antibody (anti–PD-1) added to standard R-CHOP chemotherapy for certain people with diffuse large B-cell lymphoma (DLBCL) who have a p53 mutation and tumor PD-L1 expression. It may help shrink lymphoma more effectively when these tumor markers are present.
This trial tests if the drug dexrazoxane can protect the heart during chemotherapy for a type of lymphoma called DLBCL. It may be an option for patients starting a standard treatment regimen known as R-CHOP.
This study looks at how your body's metabolism (processing of food and medicine) changes after you start treatment for lymphoma. It uses two safe, commonly used drugs (omeprazole and dextromethorphan) to measure these changes.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.